Clinical outcomes of pembrolizumab plus chemotherapy for postoperative recurrent esophageal squamous cell carcinoma
First-line pembrolizumab plus chemotherapy for postoperative recurrent esophageal cancer improved clinical outcomes compared to conventional CF therapy and can be expected to be one of the treatment options even in early postoperative recurrence.
Authors
- Yuki Ushimaru (ORCID: https://orcid.org/0000-0003-1096-0980)
- Yoshinori Kagawa (ORCID: https://orcid.org/0000-0001-6876-4507)
- Yoshitomo Yanagimoto (ORCID: https://orcid.org/0000-0001-6369-6023)
- Hiroshi Wada (ORCID: https://orcid.org/0000-0003-0510-5744)
- Hisateru Komatsu
- Junichi Nishimura
- Ryota Mori
- Yasunori Masuike (ORCID: https://orcid.org/0000-0003-2793-3129)
- Toshinori Sueda (ORCID: https://orcid.org/0000-0002-7459-7458)
- Masatoshi Kitakaze (ORCID: https://orcid.org/0000-0003-0497-7639)
- Norihiro Matsuura (ORCID: https://orcid.org/0000-0001-8956-4600)
- Takahito Sugase (ORCID: https://orcid.org/0000-0003-4645-2056)
- Tomohira Takeoka (ORCID: https://orcid.org/0000-0002-5153-6740)
- Keijiro Sugimura (ORCID: https://orcid.org/0000-0002-5100-9377)
- Takashi Kanemura
- Masayoshi Yasui (ORCID: https://orcid.org/0000-0001-6391-3630)
- Yosuke Mukai (ORCID: https://orcid.org/0000-0002-4951-8033)
- Masahiko Kubo
- Hiroshi Miyata
Institutions
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Diseases of the Esophagus
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1093/dote/doaf029
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01